Naloxone abolishes the inhibiting effect of somatostatin on the release of oxytocin evoked by insulin-induced hypoglycemia in humans.
The effect of somatostatin (SRIH) on the release of oxytocin (OT) in response to hypoglycemia during insulin tolerance test (ITT) was studied in seven normal men. Subjects were injected intravenously with 0.15 U/kg insulin alone (control test) or together with SRIH (4.1 micrograms/min x 90 min), naloxone (10 mg in an IV bolus), or the combination of the two substances. Plasma OT concentrations rose significantly during ITT; the OT response was significantly reduced by the treatment with SRIH and increased in the presence of naloxone. When both SRIH and naloxone were given, the OT response to hypoglycemia did not differ from that observed in the control test. These findings provide evidence that the effect of hypoglycemia on plasma OT levels is sensitive to the inhibition by SRIH and by naloxone-sensitive endogenous opioids. Because naloxone reversed the inhibiting effects of SRIH, an involvement of opioid peptides in SRIH action might be supposed. Alternatively, SRIH and naloxone-sensitive opioids might produce their inhibiting effects on OT rise in response to hypoglycemia through independent pathways.
Chiodera
P
P
Cattedra di Endocrinologia e Patologia Costituzionale, Università di Parma, Italy.
Gnudi
A
A
Bianconi
L
L
Capretti
L
L
Fagnoni
F
F
Volpi
R
R
Coiro
V
V
D000328:Adult; D004347:Drug Interactions; D006801:Humans; D007003:Hypoglycemia / Q000097:blood*; D007328:Insulin; D007700:Kinetics; D008297:Male; D009270:Naloxone / Q000494:pharmacology*; D010121:Oxytocin / Q000097:blood / Q000378:metabolism*; D013004:Somatostatin / Q000494:pharmacology*
D007328:Insulin; D009270:Naloxone; D010121:Oxytocin; D013004:Somatostatin